Click below to learn more about how HEMLIBRA may help all your hemophilia A patients.

HEMLIBRA has a half-life measured in weeks—not hours. 1
Learn about HEMLIBRA’s half-life.

HEMLIBRA was studied in the largest clinical trial program in hemophilia A. 3
See our treated bleeds data.

HEMLIBRA is the only subcutaneous prophylactic treatment for all people with hemophilia A. 1

Choose from QW, Q2W, and Q4W dosing options (after 4 weekly loading doses). 1
Discover flexible dosing.

Consistent safety profile evaluated in the largest clinical trial program of patients with hemophilia A over the course of 5 years. 1-7  
Learn about the demonstrated safety profile of HEMLIBRA.

More than 6100 people have been treated with HEMLIBRA worldwide 2

FVIII=factor VIII; QW=once weekly; Q2W=once every 2 weeks; Q4W=once every 4 weeks.